Nutriband Inc. reported its financial results for the three months ending April 30, 2026, revealing a revenue of $433,399, a decrease of 35% from $667,432 in the same period last year. The company's cost of revenues also fell to $236,598 from $415,451, resulting in a gross profit of $196,801, down from $251,981. The net loss for the quarter was $1,241,956, or $0.10 per share, an improvement from the net loss of $1,388,869, or $0.12 per share, reported in the prior year. The decline in revenue was attributed to a significant customer moving operations overseas, which impacted sales in the Pocono Pharmaceuticals segment.
In terms of operational metrics, Nutriband's total assets decreased to $6,892,302 as of April 30, 2026, from $7,547,935 at the end of January 2026. Current assets also fell to $4,376,262, while current liabilities increased to $832,137, leading to a working capital of $3,544,125. The company’s cash and cash equivalents stood at $4,006,184, down from $4,574,857 at the end of the previous quarter. The total stockholders' equity decreased to $5,989,990 from $6,679,488, primarily due to the net loss incurred during the quarter.
Strategically, Nutriband continues to focus on its lead product, the AVERSA Fentanyl transdermal system, which is designed to deter abuse. The company has entered into a commercial development and clinical supply agreement with Kindeva Drug Delivery to advance this product. Additionally, Nutriband has expanded its development pipeline to include other abuse deterrent products, such as AVERSA Buprenorphine and AVERSA Methylphenidate. The company has also been active in managing its capital structure, having completed an $8,400,000 equity financing with European investors in April 2024.
Looking ahead, Nutriband's management expressed optimism about its ability to generate sufficient funds from operations to support its activities over the next year. The company has been actively working to improve its financial position and operational efficiency, including hiring qualified accounting personnel to enhance internal controls. However, the company acknowledges the ongoing risks associated with product development, regulatory approvals, and market conditions that could impact its future performance. The management's forward-looking statements indicate a cautious but hopeful outlook as they navigate the challenges of the pharmaceutical industry.
About NutriBand Inc.
Nutriband Inc. develops transdermal pharmaceutical products, focusing on abuse-deterrent patches for opioids and stimulants. Its core technology, AVERSA, aims to reduce drug abuse, misuse, and accidental exposure. The company collaborates with contract manufacturers and research organizations, targeting markets in the U.S. and internationally. Its business model emphasizes innovative drug delivery systems, regulatory approval pathways, and intellectual property protection to address unmet needs in pain management and addiction treatment.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.